Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

NCT07444814 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

226

Enrollment

INDUSTRY

Sponsor class

Conditions

Endometrial Cancer
Ovarian Cancer
Ovarian Cancer Metastatic
Ovarian Cancer Metastatic Recurrent
Non-squamous EGFR Wt NSCLC
Platinum Resistant Ovarian Cancer
PROC

Interventions

DRUG: HWK-007

Sponsor

Whitehawk Therapeutics, Inc.